Variable name;level;Overall;Yes;No;p;test
;n;1357;447;909;;
Age;[0 -30);95;72 (75.8);23 (24.2);<0.001;
;[30 -35);246;173 (70.3);73 (29.7);;
;[35 -40);460;162 (35.2);298 (64.8);;
;40+;554;40 (7.2);514 (92.8);;
Number of children;0;373;231 (62.1);141 (37.9);<0.001;
;1;279;99 (35.5);180 (64.5);;
;More than 1;705;117 (16.6);588 (83.4);;
BMI;<18.5;79;30 (38);49 (62);0.002;
;25-29.9;257;88 (34.4);168 (65.6);;
;>=30;107;20 (18.7);87 (81.3);;
;18.5-24.9;807;299 (37.1);508 (62.9);;
Treatment center;Curie Paris;818;287 (35.1);531 (64.9);0.047;
;Curie St Cloud;538;160 (29.7);378 (70.3);;
Hereditary predisposition;No;547;240 (44);306 (56);0.235;
;Yes;140;70 (50);70 (50);;
Inflammatory BC;No;1338;443 (33.1);895 (66.9);0.469;
;Yes;18;4 (22.2);14 (77.8);;
Clinical Tumor size (mm);;30.3 (21.7);31.5 (20.3);29.7 (22.4);0.148;
Clinical N stage (TNM);N0;854;281 (32.9);573 (67.1);0.603;
;N1;482;162 (33.6);320 (66.4);;
;N2;7;3 (42.9);4 (57.1);;
;N3;3;0 (0);3 (100);;
SBR grade;Grade I;58;16 (27.6);42 (72.4);0.006;
;Grade II;528;150 (28.4);378 (71.6);;
;Grade III;760;278 (36.6);482 (63.4);;
Histological type;Lobular;54;8 (14.8);46 (85.2);0.014;
;NST;1265;426 (33.7);839 (66.3);;
;Others;36;13 (36.1);23 (63.9);;
Neoajuvant chemotherapy;No;744;201 (27);543 (73);<0.001;
;Yes;612;246 (40.2);366 (59.8);;
Chemotherapy setting;Adjuvant;744;201 (27);543 (73);<0.001;
;Chemotherapy without surgery;1;1 (100);0 (0);;
;NAC;611;245 (40.1);366 (59.9);;
